selumetinib
Showing 1 - 25 of 50
Chronic Myeloid Leukemia, Myelofibroses Trial in Chicago (Azacitidine, Selumetinib)
Recruiting
- Chronic Myeloid Leukemia
- Myelofibroses
- Azacitidine
- Selumetinib
-
Chicago, IllinoisThe University of Chicago
May 16, 2022
Neurofibromatosis Type 1 Trial in Japan (Selumetinib)
Active, not recruiting
- Neurofibromatosis Type 1
- Selumetinib
-
Minato-ku, Japan
- +3 more
Jun 9, 2022
NSCLC Trial in Boston, Durham (Osimertinib, Selumetinib)
Active, not recruiting
- Non-small Cell Lung Cancer
- Osimertinib
- Selumetinib
-
Boston, Massachusetts
- +3 more
Aug 1, 2022
Malignant Tumor of Breast, Malignant Tumors of Digestive Organs, Malignant Tumors of Female Genital Organs Trial in Houston
Recruiting
- Malignant Neoplasm of Breast
- +4 more
- Selumetinib
- Olaparib
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Dec 29, 2021
Neurofibromatosis Type 1 Trial in Worldwide (Selumetinib)
Active, not recruiting
- Neurofibromatosis Type 1
- Selumetinib
-
Rochester, Minnesota
- +8 more
May 4, 2022
Malignant Peripheral Nerve Sheath Tumors, Neurofibromatosis 1 Trial in United States (Selumetinib, Sirolimus)
Active, not recruiting
- Malignant Peripheral Nerve Sheath Tumors
- Neurofibromatosis 1
- Selumetinib
- Sirolimus
-
Washington, District of Columbia
- +4 more
Apr 1, 2022
Neurofibromatosis Type 1, Plexiform Neurofibroma, Optic Nerve Glioma Trial in London (Selumetinib)
Recruiting
- Neurofibromatosis Type 1
- +2 more
- Selumetinib
-
London, United Kingdom
- +1 more
Nov 11, 2021
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8 Trial in Houston
Recruiting
- Recurrent Lung Non-Small Cell Carcinoma
- +3 more
- Durvalumab
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Oct 30, 2021
Biliary Tract Carcinoma, Gallbladder Carcinoma Trial in Toronto (Selumetinib, Cisplatin, Gemcitabine)
Active, not recruiting
- Biliary Tract Carcinoma
- Gallbladder Carcinoma
- Selumetinib
- +2 more
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Apr 14, 2021
MPNST, NF1, Sarcoma Trial in United States (Selumetinib)
Not yet recruiting
- MPNST
- +2 more
- Selumetinib
-
Birmingham, Alabama
- +13 more
Jun 29, 2022
Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Adult, Acute Lymphoblastic Leukemia, Pediatric Trial in Denmark,
Recruiting
- Acute Lymphoblastic Leukemia
- +4 more
- Selumetinib
- Dexamethasone
-
Copenhagen, Denmark
- +16 more
Jan 26, 2022
Neurofibromatosis 1, Plexiform Neurofibroma (PN) Trial in Worldwide (Selumetinib, Placebo)
Active, not recruiting
- Neurofibromatosis 1
- Plexiform Neurofibroma (PN)
- Selumetinib
- Placebo
-
Gainesville, Florida
- +37 more
Jun 21, 2022
NSCLC Trial in Canada (Selumetinib, Pemetrexed, Cisplatin)
Completed
- Non-Small Cell Lung Cancer
- Selumetinib
- +3 more
-
Calgary, Alberta, Canada
- +11 more
May 28, 2021
Stage IIIB NSCLC AJCC v7, Stage IV NSCLC AJCC v7 Trial in Portland (Laboratory Biomarker Analysis, Paclitaxel, Pharmacological
Completed
- Stage IIIB Non-Small Cell Lung Cancer AJCC v7
- Stage IV Non-Small Cell Lung Cancer AJCC v7
- Laboratory Biomarker Analysis
- +3 more
-
Portland, OregonOHSU Knight Cancer Institute
Aug 11, 2020
NF type1 With Inoperable Plexiform Neurofibromas Trial in New Orleans (Selumetinib)
Approved for marketing
- NF type1 With Inoperable Plexiform Neurofibromas
- Selumetinib
-
New Orleans, LouisianaResearch Site
Apr 30, 2020
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer Trial in San Francisco, Columbus
Completed
- Adenocarcinoma of the Pancreas
- +3 more
- erlotinib hydrochloride
- +2 more
-
San Francisco, California
- +1 more
Jul 29, 2020
Non Small Cell Lung Cancer Trial in Canada (Paclitaxel, Carboplatin, Selumetinib)
Completed
- Non Small Cell Lung Cancer
- Paclitaxel
- +4 more
-
Vancouver, British Columbia, Canada
- +3 more
Apr 6, 2020
Lung Cancer, Melanoma, Head and Neck Carcinoma Trial in United States (Selumetinib, MEDI4736, Tremelimumab)
Completed
- Lung Cancer
- +7 more
- Selumetinib
- +2 more
-
Chicago, Illinois
- +5 more
Nov 15, 2019
Borderline Ovarian Serous Tumor, Low Grade Ovarian Serous Adenocarcinoma, Micropapillary Serous Carcinoma Trial in United States
Completed
- Borderline Ovarian Serous Tumor
- +5 more
- Laboratory Biomarker Analysis
- +3 more
-
Los Angeles, California
- +48 more
Dec 2, 2020
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV Trial in Worldwide (Selumetinib, Docetaxel, Placebo)
Active, not recruiting
- Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
- Selumetinib
- +3 more
-
Aurora, Colorado
- +195 more
Mar 11, 2022
Metastatic Breast Cancer Trial in France (AZD2014, AZD4547, AZD5363)
Active, not recruiting
- Metastatic Breast Cancer
- AZD2014
- +18 more
-
Angers, France
- +24 more
Mar 8, 2022
Muscle Invasive Bladder Cancer Trial in Worldwide (AZD4547, MEDI4736, Olaparib)
Active, not recruiting
- Muscle Invasive Bladder Cancer
- AZD4547
- +6 more
-
Los Angeles, California
- +26 more
May 19, 2022
Differentiated Thyroid Cancer Trial in Worldwide (Selumetinib, Placebo, Radioactive Iodine Therapy)
Terminated
- Differentiated Thyroid Cancer
- Selumetinib
- +2 more
-
Birmingham, Alabama
- +44 more
Aug 27, 2019
NSCLC, Carcinoma, Squamous Cell, Adenocarcinoma Trial in United Kingdom (AZD4547, Vistusertib, Palbociclib)
Active, not recruiting
- Non-Small Cell Lung Cancer
- +2 more
- AZD4547
- +10 more
-
Aberdeen, United Kingdom
- +24 more
Nov 2, 2021
Colorectal Tumors, Gastrointestinal Tumors, Pancreatic Tumors Trial in Nijmegen, Amsterdam (Afatinib, Selumetinib, Docetaxel)
Unknown status
- Colorectal Neoplasms
- +3 more
- Afatinib
- +2 more
-
Nijmegen, Gelderland, Netherlands
- +1 more
Aug 24, 2018